The advances in biomarker discovery for Alzheimer's disease (AD) revolutionize the clinical practice and patient management. In the revised criteria for diagnosis and staging of AD from Alzheimer's Association published last year, AD is defined by its biological process. As a disease continuum, AD is first evident in vivo with the appearance AD neuropathologic change evidenced by disease-specific Core biomarkers while people are still asymptomatic. Cerebrospinal, plasma and imaging biomarkers specific for AD pathologies and reflections of underlying non-specific processes involved in AD pathophysiology are essential for accurate and timely detection of AD. Our group has established large-scale ethnic Han-Chinese AD patient and control cohort with multi-omics databases in Hong Kong. One of our foci is plasma AD biomarkers discovery. Here, we will illustrate pros & cons of integrating various biomarkers into daily clinical practice of AD. We will also share our research findings on the amyloid PET analysis in our AD cohort and discuss the importance of adopting centiloid measurement in AD diagnosis and management.
